Dr. Mustapha Aouida received his PhD in Molecular and Cell Biology in 2003 from both the Science University of Tunis and Gustave Roussy Institute, Paris. For his post-doctoral fellowship he joined Professor Ramotar at Maisonneuve-Rosemont Research Institute in Montreal where he studied the mechanism by which yeast cells and mammalian cells become resistant to the antitumor drug bleomycin. Dr. Aouida joined the College of Health and Life Sciences in April 2016 as a Lab Manager and is currently a Research Scientist at the college.
Genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology is revolutionizing the study of gene function and likely will give rise to an entire new class of therapeutics for a wide range of diseases. Achieving this goal requires not only characterization of the technology for efficacy and specificity but also optimization of its delivery to the target cells. My laboratory is particularly interested to improve the efficiency and the specificity of CRISPR/Cas9 system and also to investigate the use of this technology in some applications such as cancer drug target discovery and understanding the molecular basis of diabetes and obesity.
College of Health and Life Sciences
2019 - PresentDivision of Life Sciences, College of Science and Engineering, Hamad Bin Khalifa University
2016 - 2018Genome Engineering Laboratory, King Abdullah of Science and Technology
2010 - 2015Maisonneuve Research Center, University of Montreal
2003 - 2010Gustave Roussy Institute, Paris (France); Science University Of Tunis, Tunisia
2003Science University Of Tunis, Tunisia
1999Bachelor in Natural Sciences
1997Technical High School Zarzis, Tunisia
1993Yeast lacking the PP2A phosphatase regulatory subunit Rts1 sensitizes rad51 mutants to specific DNA damaging agents. Front. Genet. 2019 Nov 8;10:1117. doi: 10.3389/fgene.2019.01117. eCollection 2019
2019The Budding Yeast Saccharomyces Cerevisiae as A Model System for Anti-Cancer Drug Screening. Clinics of Oncology 1 (6) 1-3.
2018Identification of essential yeast genes involved in polyamine resistance. Gene https://doi.org/10.1016/j.gene.2018.08.066 In press
2018CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B. Biochimie Open. 2016 Feb 24;3:72-75. doi: 10.1016/j.biopen.2016.02.001. eCollection 2016 Dec.
2015Generation of an Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering. PLoS One. 2015 Jul 30;10(7):e0133373. doi: 10.1371/journal.pone.0133373. eCollection 2015.
2015Efficient Viral-Mediated Genome Editing in Plants using the CRISPR/Cas9 System (2015). Mol Plant. 2015 Mar 6. pii: S1674-2052(15)00162-8. doi: 10.1016/j.molp.2015.02.011
2015The use of transcription activator- J Biosci Bioeng. 2015 Apr 20. pii: S1389-1723(15)00095-X. doi: 10.1016/j.jbiosc.2015.02.017
2015RNA-guided transcriptional regulation in planta via synthetic dCas9- based transcription factors. Plant Biothechnology 2015 May; 13(4):578-89.
2015Activities and Specificities of homodimeric TALENs in Saccharomyces cerevisiae. Current genetics (2013). In press
2013A split luciferase method to identify Adiponectin receptors agonists using Saccharomyces cerevisiae as a model organism. PLoS One. 2013 Jun 7;8(6):e65454. doi: 10.1371/journal.pone.0065454. Print 2013
2013AGP2 Encodes a Multifunctional Transceptor that Positively Regulates Polyamine Transport. PLoS One. 2013 Jun 3;8(6):e65717. doi: 10.1371/journal.pone.0065717. Print 2013
2013Characterization and DNA Binding Specificities of Ralstonia TAL-like Effectors. Mol Plant. 2013 Jan 8.
2013Book Chapter, DNA repair in cancer therapy Cancer Drug Discovery and Development (2012) Edited by Lawrence C. Panasci and Moulay A. Alaoui-Jamali In Press.
2012Functional Characterization of Osput1 A Spermidine Preferential Transporter In Rice. Planta (2012) Jan;235(1):1-11.
2012A potential transporter to revamp therapy with the anticancer drug bleomycin. Curr Drug Metab. 2010 Sep; 11(7):595-602.
2010Internalization of a thiazole-modified peptide in Sinorhizobium meliloti occurs by BacA – dependent and independent mechanisms. Microbiology, 2010 Sep; 156(Pt 9): 2702 -13
2010New Gateway to Treat Leukemia and Other Cancers, Science Daily (Mar, 27, 2010). http:// www.sciencedaily.com/releases/2010/03/100325113425.htm
2010The Human Carnitine Transporter SLC22A16 Mediates High Affinity Uptake of the Anticancer Polyamine Analogue Bleomycin-A5 J. Biol. Chem. 2010 285: 6275-6284
2010The Na+/H+ Exchanger Nhx1 of Saccharomyces cerevisiae is Essential to Limit Drug Toxicity. Advanced Studies in Biology, Vol. 2, 2010, no. 1, 15 – 34
2010Novel role for the Saccharomyces cerevisiae oligopeptidetransporter Opt2 in vacuolar assembly and drug detoxification. Biochem and Cell Biology 2009: Vol 87 653-661.
2009A potential mechanism of resistance to the anticancer drug bleomycin. In: Mohan RM, editor. Research Advances in Cancer: Vol., Part, Kerala, India, Global Research Network 247-260, 2007.
2007Mitochondria-independent morphological and biochemical apoptotic alterations promoted by the antitumor agent bleomycin in S. cerevisiae. (2007) Biochemistry and Cell Biology. Vol. 85 No. 1 Pages 49-55.
2007Bleomycin transport holds the key for improved anticancer therapy. Review Article. (2006). Cancer Therapy Vol 4, 171-182.
2006A defect (spt10) in chromatin remodeling sensitizes yeast cells to a subclass of DNA damaging agents. (2006). Environ Mol Mutagen. 47(9):707-17.
2006AGP2 encodes the major permease for high affinity polyamine import in Saccharomyces cerevisiae. J Biol Chem. (2005): 280(25): 24267-24276
2005Isolation and characterization of Saccharomyces cerevisiae mutants with enhanced resistance to the anticancer drug bleomycin. Current Genet. 2004 May; 45(5):265-72
2004A genome-wide screen in Saccharomyces cerevisiae reveals altered transport as a major mechanism of resistance to the anticancer drug bleomycin. Cancer Res. 2004 Feb 1; 64(3):1102-9.
2004Characterization of the transport and detoxification pathway for the antitumor drug bleomycin in Saccharomyces cerevisiae. Biochem J. 2004 Nov 15; 384(Pt 1):47-58.
2004Etude comparative de la cytotoxicité de deux antibiotiques antitumoraux, la bléomycine et laphléomycine, sur trois souches de la levure Saccharmyces cerevisiae. Microbiologie Hygiene et Alimentaire Vol. 16 :46 (2004) : 44-50.
2004Comparative roles of cell wall and cell membrane in limiting xenobiotic molecules uptake by Saccharomyces cerevisiae. Antimicrobial Agents and Chemotherapy 2003 Jun; 47(6):2012-4.
2003Yeast excellent model to study apoptosis. Microbiologie Hygiene et Alimentaire Vol.15 :42 (2003).
2003